{"name":"DIAMOND BIOPHARM LIMITED","company_number":"05460964","status":"Active","type":"Private Limited Company","incorporated":"2005-05-24","dissolved":null,"registered_office":"Olliver, Aske, Richmond, North Yorkshire, England, DL10 5HX","postcode":"DL10 5HX","sic_codes":[{"code":82990,"description":"Other business support service activities not elsewhere classified"}],"principal_activity":null,"previous_names":[],"warnings":["The most recent accounts indicate this company is dormant and not trading."],"accounts":{"category":"Dormant","year_end":"29 December","last_made_up_to":"2025-12-31","next_due":"2027-09-29"},"employees":{"count":33,"accounts_date":"2021-03-01"},"financials":[{"financial_date":"2021-03-01","profit_loss":-201293,"net_assets":2492617,"cash":2079077,"average_employees":33},{"financial_date":"2020-05-31","profit_loss":820513,"net_assets":2358868,"cash":1175269,"average_employees":33},{"financial_date":"2019-05-31","net_assets":2086111,"cash":830311},{"financial_date":"2018-05-31","cash":777147},{"financial_date":"2017-05-31","cash":946076}],"officers":{"current":4,"resigned":12,"complete":true,"note":"Names and details of individual officers are on the People page (subscriber-only on this site) and free at Companies House."},"charges":{"total":0,"outstanding":0},"gazette_notices":[],"insolvency_outcome":null,"ai_summary":"Diamond Biopharm Limited represents a strong-performing UK regulatory affairs boutique that achieved approximately 9x balance sheet growth over a decade before being acquired by ProPharma Group — a transaction emblematic of the broader consolidation trend in pharmaceutical consultancy. The company's financial profile — consistent profitability, exceptional liquidity, and steady organic growth — placed it well above typical performance benchmarks for UK business support services SMEs, while its specialist niche positioning commanded premium margins. The transition to dormant status reflects successful post-acquisition integration rather than business failure, though the original firm's scale and single-geography limitations would have constrained its standalone strategic options in an increasingly globalised and technology-driven regulatory market.","website":"https://www.propharmagroup.com","links":{"page":"https://www.companiesintheuk.co.uk/ltd/diamond-biopharm","people":"https://www.companiesintheuk.co.uk/company/diamond-biopharm/people","filing_history":"https://www.companiesintheuk.co.uk/company/diamond-biopharm/filing-history","companies_house":"https://find-and-update.company-information.service.gov.uk/company/05460964","financials":"https://www.companiesintheuk.co.uk/company/diamond-biopharm/financial","control":"https://www.companiesintheuk.co.uk/company/diamond-biopharm/control","charges":"https://www.companiesintheuk.co.uk/company/diamond-biopharm/charges","ai_analysis":"https://www.companiesintheuk.co.uk/company/diamond-biopharm/analysis"},"source":"CompaniesInTheUK, from Companies House, The Gazette and other public registers (see /support/about). Cite as: CompaniesInTheUK, https://www.companiesintheuk.co.uk/ltd/diamond-biopharm"}